AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall

Zinger Key Points
  • AbbVie says fiscal year 2024 adjusted EPS guidance includes dilutive impact related to ImmunoGen and Cerevel Therapeutics acquisitions.
  • AbbVie has reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.

Friday, AbbVie Inc ABBV reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77.

Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion.

The immunology portfolio generated $6.95 billion in sales, down 12.3%.

Humira revenues were $3.30 billion (down 40.8%), Skyrizi sales reached $2.39 billion (up 51.9%), and Rinvoq revenues were $1.26 billion (up 62.9%). 

Related: Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition.

Oncology product sales were $1.51 billion, down 7.4%. Imbruvica revenues were $903 million (down 19%), and Venclexta sales increased 14.3% to $589 million.

In November, AbbVie agreed to acquire ImmunoGen Inc IMGN and its flagship cancer therapy, Elahere, for $31.26 per share in cash, with an equity value of approximately $10.1 billion

Neuroscience revenues increased 22.6% to $2.09 billion. Botox Therapeutic sales were $776 million, up 6.6%.

Read Next: Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings.

Aesthetics portfolio sales reached $1.37 billion, up 6.4%. Global Botox Cosmetic revenues were $718 million, up 11.8%.

During the quarter, AbbVie agreed to acquire Cerevel Therapeutics Holdings Inc CERE for a total equity value of approximately $8.7 billion, or $45 per share in cash, to boost its neurological portfolio.

Guidance: AbbVie expects fiscal year 2024 adjusted EPS of $11.05-$11.25, which includes a $0.32/share dilutive impact related to ImmunoGen and Cerevel Therapeutics acquisitions, versus the consensus of $11.29.

AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. 

The company raised its long-term outlook for Skyrizi and Rinvoq revenues and expects combined 2027 revenues of over $27 billion, compared to over $21 billion expected earlier.

AbbVie also raised its long-term outlook for Ubrelvy and Qulipta and forecasts peak combined revenues of over $3 billion, up from previous guidance for peak revenues of over $1 billion for each asset.

Price Action: ABBV shares are up 1.44% at $170.01 on the last check Friday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefsStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!